Provided by Tiger Trade Technology Pte. Ltd.

Prothena Corp PLC

9.83
+0.42004.46%
Pre-market: 10.000.1700+1.73%05:11 EDT
Volume:510.85K
Turnover:5.01M
Market Cap:514.63M
PE:-3.49
High:10.00
Open:9.36
Low:9.36
Close:9.41
52wk High:11.80
52wk Low:4.32
Shares:52.35M
Float Shares:38.17M
Volume Ratio:0.85
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8131
EPS(LYR):-4.5346
ROE:-40.30%
ROA:-13.78%
PB:1.65
PE(LYR):-2.17

Loading ...

Prothena shareholders re-elect directors at annual meeting

Reuters
·
May 16

Prothena files Form 3 initial beneficial ownership statement for William P. Scully

Reuters
·
May 15

Prothena Corp. Down Over 9%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk

Dow Jones
·
May 12

Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA) and Eli Lilly & Co (LLY)

TIPRANKS
·
May 10

Prothena Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 08

Prothena price target raised to $20 from $19 at Citizens

TIPRANKS
·
May 08

Prothena cuts FY26 net cash used view to $18M-$23M from $50M-$55M

TIPRANKS
·
May 08

Prothena Corporation PLC reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment

Reuters
·
May 08

Prothena publishes corporate overview presentation on protein dysregulation disease pipeline

Reuters
·
May 08

Prothena Q1 FY26 swings to net profit of $32.7 million; revenue more than doubled to $51.1 million

Reuters
·
May 08

Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate

Benzinga
·
May 08

BRIEF-Prothena Q1 Net Income USD 32.721 Million

Reuters
·
May 08

Prothena Corporation Plc - Updates FY2026 Net Cash Used in Operating and Investing Activities to $18-$23 Mln

THOMSON REUTERS
·
May 08

Prothena Q1 EPS USD 0.6

THOMSON REUTERS
·
May 08

Prothena Corporation PLC expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
May 06

Press Release: Prothena to Report First Quarter 2026 Financial Results on May 7

Dow Jones
·
May 01

Prothena to report first-quarter results after U.S. market close

Reuters
·
May 01

Prothena says FDA grants Fast Track designation to Novo Nordisk’s coramitug PRX004 for ATTR-CM

Reuters
·
Apr 28

Prothena Corporation Plc - Coramitug Phase 3 Cleopattra Trial Enrolls ~1,280 Participants; Primary Completion Expected in 2029

THOMSON REUTERS
·
Apr 28